Real-World Twelve-Month Weight Loss Outcomes in a Comprehensive Obesity Care Program Utilizing Individualized Nutrition Therapy and Incretin-Based Obesity Medications
- 1Virta
Abstract
BackgroundIncretin-based obesity medications (IOMs) produce substantial weight loss, but the incremental benefit of structured nutritional therapy when integrated with pharmacotherapy remains unclear.
ObjectivesTo compare 12-month weight-loss outcomes between individualized carbohydrate-reduced nutritional therapy combined with IOMs (VINT+IOM) and IOM-based care without structured nutritional therapy (IOM only).
MethodsThis retrospective cohort study evaluated 4,269 adults enrolled in a comprehensive telemedicine obesity care program (VINT+IOM, n=1,658; IOM only, n=2,611). Both pathways included clinician-guided medication management and behavioral coaching. The primary analysis focused on GLP-1-naive participants receiving a single medication ingredient (semaglutide or tirzepatide). Adjusted weight changes were estimated using longitudinal linear mixed-effects models. Additional analyses evaluated weight-loss responders, prior GLP-1 exposure, and medication utilization.
ResultsAmong GLP-1-naive semaglutide users, adjusted 12-month weight loss was greater with VINT+IOM than IOM only (30.7 vs. 24.1 lb; P=0.01), with corresponding observed weight loss of 13.3% versus 11.1%. Among tirzepatide users, adjusted weight loss was 45.9 versus 34.4 lb (P=0.003), with observed reductions of 19.7% versus 15.6%, respectively. Weight-loss responder rates consistently favored VINT+IOM. In the overall cohort (GLP-1 naive, prior users and all other treatment trajectories), adjusted weight loss was 29.4 versus 21.5 lb (P<0.001), with observed reductions of 12.7% versus 9.6%. Greater weight loss with VINT+IOM was also observed among participants with prior GLP-1 exposure. Weight loss continued between 6 and 12 months in both pathways. Medication coverage was high, with approximately 80% of participants achieving proportion of days covered [≥]80% in both pathways.
ConclusionsIntegrating individualized carbohydrate-reduced nutritional therapy with IOM-based care was associated with greater 12-month weight loss than IOM-based care without structured nutritional therapy. These real-world findings support further evaluation of individualized nutritional approaches as an adjunct to incretin-based obesity pharmacotherapy.
Related
- Quality-of-Life and Weight Loss Outcomes Following an Individualized Nutrition and Physical Activity Counseling Program in Breast Cancer Survivors: A Prospective Single-Arm Pilot Study
- Prospective Evaluation of Individualized Nutrition Support on the Incidence of High-Output Ileostomy
- The pharmacist's role in enhancing adherence to GLP1 based anti-obesity medications through comprehensive side effect management
- Medications for alcohol use disorder in Alcohol-Associated Liver Disease: The Role of Gastroenterologist and Hepatologist in Treatment and Outcomes
- Novel liquid biopsy based on comprehensive small RNA profiling for screening of cancer in dogs utilizing machine learning.
BibTeX
@misc{athinarayanan2026realworld,
title = {{Real-World Twelve-Month Weight Loss Outcomes in a Comprehensive Obesity Care Program Utilizing Individualized Nutrition Therapy and Incretin-Based Obesity Medications}},
author = {S. Athinarayanan and A. R. Zoller and K. E. Bergethon and A. M. Goss and B. A. Gower},
howpublished = {medRxiv},
year = {2026},
month = oct,
doi = {10.64898/2026.10.09.26365158},
url = {https://www.medrxiv.org/content/10.64898/2026.10.09.26365158v1},
note = {CC BY-NC},
}
RIS
TY - UNPB
TI - Real-World Twelve-Month Weight Loss Outcomes in a Comprehensive Obesity Care Program Utilizing Individualized Nutrition Therapy and Incretin-Based Obesity Medications
AU - S. Athinarayanan
AU - A. R. Zoller
AU - K. E. Bergethon
AU - A. M. Goss
AU - B. A. Gower
PY - 2026
DA - 2026/10/09
PB - medRxiv
DO - 10.64898/2026.10.09.26365158
UR - https://www.medrxiv.org/content/10.64898/2026.10.09.26365158v1
AB - BackgroundIncretin-based obesity medications (IOMs) produce substantial weight loss, but the incremental benefit of structured nutritional therapy when integrated with pharmacotherapy remains unclear. ObjectivesTo compare 12-month weight-loss outcomes between individualized carbohydrate-reduced nutritional therapy combined with IOMs (VINT+IOM) and IOM-based care without structured nutritional therapy (IOM only). MethodsThis retrospective cohort study evaluated 4,269 adults enrolled in a comprehensive telemedicine obesity care program (VINT+IOM, n=1,658; IOM only, n=2,611). Both pathways included clinician-guided medication management and behavioral coaching. The primary analysis focused on GLP-1-naive participants receiving a single medication ingredient (semaglutide or tirzepatide). Adjusted weight changes were estimated using longitudinal linear mixed-effects models. Additional analyses evaluated weight-loss responders, prior GLP-1 exposure, and medication utilization. ResultsAmong GLP-1-naive semaglutide users, adjusted 12-month weight loss was greater with VINT+IOM than IOM only (30.7 vs. 24.1 lb; P=0.01), with corresponding observed weight loss of 13.3% versus 11.1%. Among tirzepatide users, adjusted weight loss was 45.9 versus 34.4 lb (P=0.003), with observed reductions of 19.7% versus 15.6%, respectively. Weight-loss responder rates consistently favored VINT+IOM. In the overall cohort (GLP-1 naive, prior users and all other treatment trajectories), adjusted weight loss was 29.4 versus 21.5 lb (P<0.001), with observed reductions of 12.7% versus 9.6%. Greater weight loss with VINT+IOM was also observed among participants with prior GLP-1 exposure. Weight loss continued between 6 and 12 months in both pathways. Medication coverage was high, with approximately 80% of participants achieving proportion of days covered [≥]80% in both pathways. ConclusionsIntegrating individualized carbohydrate-reduced nutritional therapy with IOM-based care was associated with greater 12-month weight loss than IOM-based care without structured nutritional therapy. These real-world findings support further evaluation of individualized nutritional approaches as an adjunct to incretin-based obesity pharmacotherapy.
ER -